Dergiler / Erciyes Medical Journal / 2021 / Cilt: 43 - Sayı: 3

Evaluation of the Effect of Mortality, Life Expectancy,and Treatment Modalities of Sickle Cell Patients onMortality

Sayfa
273–277
Yayın Tarihi
2022-10-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Use of hydroxyurea, use of iron chelator, exchange transfusion history, and surgical oper ation history due to SCD were not found to be significantly effective when the mean age of death reported in the literaturewas taken as the base value.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: We aimed to contribute to the literature by investigating the causes of mortality, average life expectancies, andthe clinical features that occur in this process, in relation to sickle cell disease (SCD), and by comparing the results obtainedwith other similar clinical studies.
📊
Temel Bulgular & Veri:No significantdifference was found between the premature death and late death groups, that is, the groups that we have determined on thebasis of the SCD patients ages of death, in terms of use of hydroxyurea, use of iron chelator, and use of exchange transfusiondepending on the disease.
💡
Sonuç & Katkı:Use of hydroxyurea, use of iron chelator, exchange transfusion history, and surgical oper ation history due to SCD were not found to be significantly effective when the mean age of death reported in the literaturewas taken as the base value.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: We aimed to contribute to the literature by investigating the causes of mortality, average life expectancies, andthe clinical features that occur in this process, in relation to sickle cell disease (SCD), and by comparing the results obtainedwith other similar clinical studies. Materials and Methods: This study was designed as a monocentric, cross–sectional, and retrospective study. The patientfiles were reviewed in terms of the age, use of hydroxyurea, use of chelators, exchange transfusion history, surgical operationhistory, the annual frequency of painful crises, the annual hospitalization frequency, and the annual frequency of follow–upvisits which the patients have attended, the complications experienced by the patients, and the causes of mortality. Results: Acute chest syndrome was the most prevalent cause of death of the patients included in our study. No significantdifference was found between the premature death and late death groups, that is, the groups that we have determined on thebasis of the SCD patients ages of death, in terms of use of hydroxyurea, use of iron chelator, and use of exchange transfusiondepending on the disease. Conclusion: Based on our findings, acute chest syndrome was the primary cause of death in SCD patients we have studied,followed by pulmonary embolism. Use of hydroxyurea, use of iron chelator, exchange transfusion history, and surgical oper ation history due to SCD were not found to be significantly effective when the mean age of death reported in the literaturewas taken as the base value.

🔖

Bu Makaleye Atıf Yap

İLHAN, G., KAYA, M. N. (2022). Evaluation of the Effect of Mortality, Life Expectancy,and Treatment Modalities of Sickle Cell Patients onMortality. Erciyes Medical Journal, Cilt: 43 - Sayı: 3, 273–277. https://ajindex.com/articles/502301

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Mandal AK, Mitra A, Das R. Sickle cell hemoglobin. Subcell Biochem 2020; 94: 297–322
  2. Canatan D, Kose MR, Ustundag M, Haznedaroglu D, Ozbas S. Hemoglobinopathy control program in Turkey. Community Genet 2006; 9(2): 124–6
  3. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: A neglected cause of early childhood mortality. Am J Prev Med 2011; 41(6 Suppl 4): 398–405
  4. Marcheco-Teruel B. Sickle cell anemia in Cuba: Prevention and management, 1982-2018. Med Rev 2019; 21(4): 34–8
  5. Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010; 85(6): 403–8
  6. Therrell BL Jr., Lloyd-Puryear MA, Eckman JR, Mann MY. Newborn screening for sickle cell diseases in the United States: A review of data spanning 2 decades. Semin Perinatol 2015; 39(3): 238–51
  7. Quinn CT, Rogers ZR, McCavit TL, Buchanan GR. Improved survival of children and adolescents with sickle cell disease. Blood 2010; 115(17): 3447–52
  8. Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer 2013; 60(9): 1482–6
  9. Maitra P, Caughey M, Robinson L, Desai PC, Jones S, Nouraie M, et al. Risk factors for mortality in adult patients with sickle cell disease: A meta-analysis of studies in North America and Europe. Haematologica 2017; 102(4): 626–36
  10. Karacaoglu PK, Asma S, Korur A, Solmaz S. East Mediterranean region sickle cell disease mortality trial: Retrospective multicenter cohort analysis of 735 patients. Ann Hematol 2016; 95(6): 993–1000
  11. Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers 2018; 4: 18010
  12. Ohemeng A, Boadu I. The role of nutrition in the pathophysiology and management of sickle cell disease among children: A review of literature. Crit Rev Food Sci Nutr 2018; 58(14): 2299–305
  13. Freitas SLF, Ivo ML, Figueiredo MS, Gerk MA, Nunes CB, Monteiro FF. Quality of life in adults with sickle cell disease: An integrative review of the literature. Rev Bras Enferm 2018; 71(1): 195–205
  14. Tran H, Gupta M, Gupta K. Targeting novel mechanisms of pain in sickle cell disease. Blood 2017; 130(22): 2377–85
  15. Indications of Stem Cell Transplantation in Sickle Cell Disease, Social Security Institution of Turkey; 2015. Available from: URL: http:// www.sgk.gov.tr/kemi